◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 6609

Shanghai HeartCare Medical Technology Corporation Limited (6609) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Medical Devices · DATA UPDATED 2026-08-10

Shanghai HeartCare Medical Technology Corporation Limited (6609) operates in the Medical Devices industry and is headquartered in Shanghai, China with about 367 employees. Its market capitalization is roughly CNY 2 billion. In the fiscal year ended 2025-12-31, 6609 reported CNY 408M in revenue and CNY 83M in net income.

Shanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices in Mainland China.

Interactive charts & full statements →

6609 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 408MCNY 278MCNY 232MCNY 183M
Gross ProfitCNY 290MCNY 182MCNY 164MCNY 124M
Operating Income (EBIT)CNY 78M(CNY 6M)(CNY 103M)(CNY 186M)
Net IncomeCNY 83M(CNY 14M)(CNY 94M)(CNY 200M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6609 Free Cash Flow History

6609 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 1.3BCNY 1.2BCNY 1.2BCNY 1.3B
Total LiabilitiesCNY 160MCNY 144MCNY 126MCNY 147M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6609 viewer.

Other Companies in Medical Devices

← 6608All “0-9” companies6610 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.